Effect of Percutaneous Acupoint Electrical Stimulation on Delirium

Launched by QIN ZHANG · Apr 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effect of a treatment called Transcutaneous Electrical Acupoint Stimulation (TEAS) on patients experiencing delirium after lung surgery. Delirium is a condition that can cause confusion and changes in awareness, and it can occur after operations. In this study, some participants will receive TEAS, while others will receive standard care. Researchers want to find out if TEAS can help reduce the severity and occurrence of delirium in patients following thoracoscopic lung surgery, as well as improve their recovery by looking at factors like pain, anxiety, sleep, and overall hospital stay.

To be eligible for this trial, participants need to be at least 18 years old and scheduled for lung surgery. They should not have severe mental health issues or certain medical conditions that would make participation unsafe. If someone decides to join the study, they can expect to be part of a group that may receive the new treatment or standard care, and their progress will be monitored throughout their hospital stay to see how well they recover. This trial is currently recruiting participants, and researchers hope it will lead to better ways to manage postoperative delirium.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Voluntary participation in the study;
• • Age ≥ 18 years;
• • Patients scheduled for thoracoscopic lung resection surgery;
• • ASA grade I-III.
• Exclusion Criteria:
• • History of severe central nervous system diseases, psychiatric disorders, cognitive impairment, intellectual disability, or Mini-Mental State Examination (MMSE) score ≤23;
• • History of opioid addiction, long-term use of analgesic drugs, or psychotropic drugs;
• • Severe cardiovascular and cerebrovascular diseases;
• • Severe liver and kidney dysfunction: Child-Pugh grade B, C patients, patients requiring regular dialysis, etc.;
• • Pregnant or postpartum women;
• • Patients with language communication barriers;
• • Deemed unsuitable for participation by the researchers.